TY - JOUR
T1 - Radiosynthesis and initial in vitro evaluation of [ 18F]F- PEG 6-IPQA-A novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas
AU - Pal, Ashutosh
AU - Balatoni, Julius A.
AU - Mukhopadhyay, Uday
AU - Ogawa, Kazuma
AU - Gonzalez-Lepera, Carlos
AU - Shavrin, Aleksandr
AU - Volgin, Andrei
AU - Tong, William
AU - Alauddin, Mian M.
AU - Gelovani, Juri G.
N1 - Funding Information:
Acknowledgments. This work was supported by the following grants: W81XWH-05-2-0027 (J.G.—Project Leader; Imaging Core Leader) and U24CA126577 (J.G. co-PI). We thank Karen Yoas, M.S., for the excellent coordination of studies.
PY - 2011/10
Y1 - 2011/10
N2 - Introduction: Epidermal growth factor receptor (EGFR)-targeted therapies with antibodies and small molecular EGFR kinase inhibitors have shown poor efficacy in unselected populations of patients with advanced non-small cell lung carcinomas (NSCLC). In contrast, patients with overexpression of EGFR and activating mutations in EGFR kinase domain demonstrated improved responses to EGFR kinase inhibitors. Therefore, we have developed a novel radiotracer, [ 18F]F-PEG 6-IPQA for PET imaging of EGFR expression-activity in NSCLC, and have described its radiosynthesis and in vitro evaluation in two NSCLC cell lines with wild-type and L858R active mutant EGFR. Methods: A mesylate precursor was synthesized in multiple steps and radiofluorinated using K 18F/ Kryptofix. The fluorinated intermediate compound was reduced to an amino derivative then treated with acryloyl isobutyl carbonate, followed by purification by HPLC to obtain the desired product. Results: Decay-corrected radiochemical yields of [ 18F]F-PEG 6-IPQA were 3.9-17.6%, with an average of 9.0% (n=11). Radiochemical purity was 997% with specific activity of 34 GBq/μmol (mean value, n=10) at the end of synthesis. The accumulation of [ 18F]F-PEG 6-IPQA in H3255 cells was ten-fold higher than in H441 cells, despite a two-fold lower level of activated phospho- EGFR expression in H3255 cells compared with H441 cells. The accumulation of [ 18F]F-PEG 6- IPQA in both cell lines was significantly decreased in the presence of a small molecular EGFR kinase inhibitor, Iressa, at 100 μM concentration in culture medium. Conclusion: We have synthesized [ 18F]F-PEG 6-IPQA and demonstrated its highly selective accumulation in active mutant L858R EGFR-expressing NSCLC cells in vitro. Further in vivo studies are warranted to assess the ability of PET imaging with [ 18F]F-PEG 6-IPQA to discriminate the active mutant L858R EGFR-expressing NSCLC that are sensitive to therapy with EGFR kinase inhibitors vs NSCLC that express wild-type EGFR.
AB - Introduction: Epidermal growth factor receptor (EGFR)-targeted therapies with antibodies and small molecular EGFR kinase inhibitors have shown poor efficacy in unselected populations of patients with advanced non-small cell lung carcinomas (NSCLC). In contrast, patients with overexpression of EGFR and activating mutations in EGFR kinase domain demonstrated improved responses to EGFR kinase inhibitors. Therefore, we have developed a novel radiotracer, [ 18F]F-PEG 6-IPQA for PET imaging of EGFR expression-activity in NSCLC, and have described its radiosynthesis and in vitro evaluation in two NSCLC cell lines with wild-type and L858R active mutant EGFR. Methods: A mesylate precursor was synthesized in multiple steps and radiofluorinated using K 18F/ Kryptofix. The fluorinated intermediate compound was reduced to an amino derivative then treated with acryloyl isobutyl carbonate, followed by purification by HPLC to obtain the desired product. Results: Decay-corrected radiochemical yields of [ 18F]F-PEG 6-IPQA were 3.9-17.6%, with an average of 9.0% (n=11). Radiochemical purity was 997% with specific activity of 34 GBq/μmol (mean value, n=10) at the end of synthesis. The accumulation of [ 18F]F-PEG 6-IPQA in H3255 cells was ten-fold higher than in H441 cells, despite a two-fold lower level of activated phospho- EGFR expression in H3255 cells compared with H441 cells. The accumulation of [ 18F]F-PEG 6- IPQA in both cell lines was significantly decreased in the presence of a small molecular EGFR kinase inhibitor, Iressa, at 100 μM concentration in culture medium. Conclusion: We have synthesized [ 18F]F-PEG 6-IPQA and demonstrated its highly selective accumulation in active mutant L858R EGFR-expressing NSCLC cells in vitro. Further in vivo studies are warranted to assess the ability of PET imaging with [ 18F]F-PEG 6-IPQA to discriminate the active mutant L858R EGFR-expressing NSCLC that are sensitive to therapy with EGFR kinase inhibitors vs NSCLC that express wild-type EGFR.
KW - Epidermal growth factor receptor
KW - Non-small cell lung carcinoma
KW - Positron emission tomography
KW - Radiochemistry
KW - [ F]F-PEG -IPQA
UR - http://www.scopus.com/inward/record.url?scp=84855700865&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855700865&partnerID=8YFLogxK
U2 - 10.1007/s11307-010-0408-8
DO - 10.1007/s11307-010-0408-8
M3 - Article
C2 - 20859697
AN - SCOPUS:84855700865
SN - 1536-1632
VL - 13
SP - 853
EP - 861
JO - Molecular Imaging and Biology
JF - Molecular Imaging and Biology
IS - 5
ER -